GlassScriptPhysician profile
Rashmi Jain
NPI 1346444577
$3,263.43
in general payments reported to CMS, 2019-2025
24 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $65.11 · 2021: $656 · 2022: $570 · 2023: $550 · 2024: $764 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642 · Education: $46.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.24 |
| Education | $46.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $505.05 | 2023-2025 | Tavneos, Parsabiv, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $449.05 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $412.04 | 2019-2025 | Farxiga |
| Opko Pharmaceuticals, LLC | $242.32 | 2021-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $228.26 | 2021-2023 | Velphoro |
| Calliditas Therapeutics US INC. | $215.31 | 2022-2024 | |
| Lilly USA, LLC | $142.19 | 2023-2025 | Jardiance, Mounjaro |
| Bard Peripheral Vascular, INC. | $138.67 | 2019 | |
| Boston Scientific Corporation | $128.58 | 2023 | Eluvia |
| Horizon Therapeutics Plc | $127.21 | 2022-2023 | Krystexxa |
| Novo Nordisk INC | $124.55 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $81.80 | 2022-2023 | Jynarque |
| Mallinckrodt Hospital Products INC. | $74.92 | 2024 | Acthar |
| Glaxosmithkline, LLC. | $64.45 | 2021-2025 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $60.00 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $56.81 | 2021 | |
| Arbor Pharmaceuticals, INC. | $52.08 | 2020-2021 | |
| Travere Therapeutics, INC. | $29.68 | 2025 | |
| Insmed, INC. | $28.99 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.65 | 2025 | Xifaxan |
| Daiichi Sankyo INC. | $22.15 | 2021 | |
| Vifor Pharma, INC. | $20.36 | 2021 | |
| Baxter Healthcare | $19.06 | 2019 | |
| Genentech USA, INC. | $15.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.